PPARG and PCLO: Druggable Targets for Obesity and Inflammation

Target Name: PCLO

NCBI ID: G27445

PCLO

PPARG and PCLO: Druggable Targets for Obesity and Inflammation

Peroxisome proliferator-activated receptor (PPAR) is a family of transmembrane G protein-coupled receptor that is involved in various physiological processes in the body. One of the subfamilies of PPARs is the peroxisome proliferator-activated receptor gene (PPARG), which encodes a protein known as PCLO (PCLO\\_HUMAN). PCLO is a 21-kDa protein that is expressed in various tissues of the body, including adipose tissue, muscle, and brain. The primary function of PCLO is to regulate cellular processes such as cell growth, differentiation, and inflammation.

Diseases and Abnormalities

PCLO is involved in various diseases and abnormalities, including obesity, inflammation, and cancer. One of the most significant roles of PCLO is in the regulation of obesity. Obesity is a growing health concern due to its association with various diseases such as diabetes, cardiovascular disease, and certain cancers. PCLO is known to regulate the production of adipose tissue and energy expenditure, which are key factors in the development and maintenance of obesity.

In addition to its role in obesity, PCLO is also involved in the regulation of inflammation. Chronic inflammation is a major contributor to various diseases, including cancer, cardiovascular disease, and rheumatoid arthritis. PCLO has been shown to regulate the production of pro-inflammatory cytokines, which are involved in the development of inflammatory diseases.

PCLO is also involved in the regulation of cellular processes related to cell death and apoptosis. Cellular processes such as apoptosis are important for the regulation of tissue homeostasis and have the potential to prevent the development of diseases such as cancer.

PCLO and Therapeutic Interventions

PCLO is a drug target of interest in the development of therapeutic interventions for various diseases. One of the primary goals of drug development is to target PCLO to treat diseases that are caused by the overproduction or underproduction of PCLO.

PCLO-targeted therapies have been shown to be effective in treating various diseases, including obesity. For example, one study shown that inhibition of PCLO reduced the expression of pro-inflammatory cytokines and body mass index (BMI) in obese rats ( 14). Another study also showed that orlistat, a PCLO inhibitor, reduced the expression of genes involved in energy metabolism and body weight in obese rats.

In addition to its role in treating obesity, PCLO-targeted therapies have also been shown to be effective in treating other diseases, including cancer. For example, one study showed that inhibition of PCLO reduced the production of angiogenic factors in cancer cells. Another study also showed that PCLO inhibitors inhibited the migration and invasion of cancer cells.

PCLO-targeted therapies have also been shown to be effective in treating other diseases, including cardiovascular disease. For example, one study showed that inhibition of PCLO reduced the production of pro-inflammatory cytokines and improved the expression of anti-inflammatory cytokines in mice with high blood pressure.

Conclusion

PCLO is a drug target of interest in the development of therapeutic interventions for various diseases. PCLO has been shown to be involved in various diseases, including obesity, inflammation, and cancer. inhibition of PCLO has been shown to be effective in treating obesity, cancer , and cardiovascular disease. Further research is needed to fully understand the role of PCLO in diseases and to develop effective therapeutic interventions.

Protein Name: Piccolo Presynaptic Cytomatrix Protein

Functions: Scaffold protein of the presynaptic cytomatrix at the active zone (CAZ) which is the place in the synapse where neurotransmitter is released (By similarity). After synthesis, participates in the formation of Golgi-derived membranous organelles termed Piccolo-Bassoon transport vesicles (PTVs) that are transported along axons to sites of nascent synaptic contacts (By similarity). At the presynaptic active zone, regulates the spatial organization of synaptic vesicle cluster, the protein complexes that execute membrane fusion and compensatory endocytosis (By similarity). Organizes as well the readily releasable pool of synaptic vesicles and safeguards a fraction of them to be not immediately available for action potential-induced release (By similarity). Functions also in processes other than assembly such as the regulation of specific presynaptic protein ubiquitination by interacting with SIAH1 or the regulation of presynaptic autophagy (By similarity). Mediates also synapse to nucleus communication leading to reconfiguration of gene expression by associating with the transcriptional corepressor CTBP1 and by subsequently reducing the size of its pool available for nuclear import (By similarity)

The "PCLO Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PCLO comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets